Publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly Lumryz dosing (sodium oxybate) extended-release oral suspension – Avadel Pharma
Avadel Pharmaceuticals plc , announced the publication of final data from the RESTORE open-label/switch study, demonstrating that people with narcolepsy prefer once-at-bedtime Lumryz versus a twice-nightly immediate-release oxybate treatment… read more.
